References
- Barbera L, Elit L, Krzyzanowska M et al (2010) End of life care for women with gynecologic cancers. Gynecol Oncol,118,196-201. https://doi.org/10.1016/j.ygyno.2010.04.014
- Cheung MC, Earle CC, Rangrej J et al (2015) Impact of aggressive management and palliative care on cancer costs in the final month of life. Cancer, 121, 3307-15. https://doi.org/10.1002/cncr.29485
- De Meerleer G, Vandecasteele K, Ost P et al (2011) Whole abdominopelvicradiotherapy using intensity-modulated arc therapy in the palliative treatment of chemotherapy-resistant ovarian cancer with bulky peritoneal disease: a single-institution experience. Int J Radiat Oncol Biol Phys, 79,775-81. https://doi.org/10.1016/j.ijrobp.2009.11.039
- Donovan KA, Greene PG, Shuster JL. (2002) Treatment preferences in recurrent ovarian cancer. Gynecol Oncol, 86, 200-11. https://doi.org/10.1006/gyno.2002.6748
- Fauchi J, Schneider K, Walters C et al (2012) The utilizeation of palliateive care in gynecologic oncology patients near the end of life. Gynecol Oncol, 127, 175-79. https://doi.org/10.1016/j.ygyno.2012.06.025
- Japanese Society for Palliative Medicine (2014) The 2014 White Paper on Hospices from palliative care teams. 2014 edition, Seikaisha, LTD, Tokyo.
- Hashimoto K, Yonemori K, Katsumata N et al (2009) Factors that affect the duration of the interval between the completion of palliative chemotherapy and death. Oncologist, 14, 752-59. https://doi.org/10.1634/theoncologist.2008-0257
- Kao S, Shafig J, Vardy J et al (2009) Use of chemotherapy at end of life in oncology patients. Ann Oncol, 20,1555-59. https://doi.org/10.1093/annonc/mdp027
- Keyser EA, Reed BG, Lowery WJ et al (2010) Hospice enrollent for terminally ill patients with gynecologic cancer: Impact on outcomes and intervenetions. Gynecol Oncol ,118, 274-77. https://doi.org/10.1016/j.ygyno.2010.05.021
- Kobold S, Hegewisch-Becker S, Oechsle K et al (2009) Intraperitoneal VEGF inhibition using bevacizumab: a potential approach for the symptomatic treatment of malignant ascites? Oncologist, 14, 1242-51. https://doi.org/10.1634/theoncologist.2009-0109
- Lowery WJ, Lowery AW, Barnett JC et al (2013) Cost-effectiveness of early palliative care intervention in recurrent platinum-resistant ovarian cancer. Gynecol Oncol, 130, 426-30. https://doi.org/10.1016/j.ygyno.2013.06.011
- Mack JW, Cronin A, Keating NL et al (2012) Associations between end-of-life discussion characteristics and care received near death: a prospective cohort study. J Clin Oncol 30, 4387-95. https://doi.org/10.1200/JCO.2012.43.6055
- Maeda S, Yabuuchi J, Nobuta H et al (2015) Characteristics of Patients and Their Ascites Who Underwent Repeated Cell-Free and Concentrated Ascites Reinfusion Therapy. Ther Apher Dial, 19, 342-48. https://doi.org/10.1111/1744-9987.12343
- Makino H, Nishio S, Tsubamoto H et al (2016) Treatment and prognosis of bone metastasis from cervical cancer (KCOG-G1202s). J Obstet Gynaecol Res, doi: 10.1111/jog.12956.
- Mohsen H, Haddad P, Allam A et al (2014) Patterns in place of cancer death in the state of Quatar; A population-based Study. PLoS ONE, 9, e109615. https://doi.org/10.1371/journal.pone.0109615
- Morita T, Miyashita M, Tsuneto S et al (2009) Late referrals to palliative care units in Japan: nationwide follow-up survey and effects of palliative care team involvement after the Cancer Control. Act J Pain Symptom Manage, 38, 191-96. https://doi.org/10.1016/j.jpainsymman.2008.09.011
- Murakami N, Tanabe K, Morita T et al (2015) Going back to home to die: dose it make a difference to patient survival. BMC Palliative care 14:7 doi 10.1186/s12904-015-0003-5.
- Nappa U, Lindqvist O, Rasmussen B.H et al (2011) Palliative chemotherapy during the last month of life. Ann Oncol, 22, 2375-80. https://doi.org/10.1093/annonc/mdq778
- Nevadunsky NS, Gordon S, Spoozak L et al (2014) The role and timing of palliative medicine consultation for women with gynecologic cancer: association with end of life interventions and direct hospital costs. Gynecol Oncol, 132, 3-7. https://doi.org/10.1016/j.ygyno.2013.10.025
- Pujade-Lauraine E, Hilpert F, Weber B et al (2014) Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol, 32, 1302-8. https://doi.org/10.1200/JCO.2013.51.4489
- Ramondetta LM, Tortolero-Luna G, Bodurka DC et al (2014) Approaches for end-of-life care in the field of gynecologic oncology: an exploratory study. Int J Gynecol Cancer, 14, 580-88.
- Saito AM, Landrum MB, Neville BA et al (2011) The effect on survival of continuing -chemotherapy to near death. BMC Palliat Care, 21,10-14.
- Von Gruenigen VE, Daly BJ (2005) Futility: clinical decisions at the end-of-life in women with ovarian cancer. Gynecol Oncol, 97,638-44. https://doi.org/10.1016/j.ygyno.2005.01.031
- Wang L, Okubo T, Shinsaka M et al (2015) Efficacy and safety of cell-free and concentrated ascites reinfusion therapy (CART) in gynecologic cancer patients with a large volume of ascites. J Obstet Gynaecol Res, 41, 1614-20. https://doi.org/10.1111/jog.12763
- Wright AA, Keating NL, Balboni TA et al (2010) Place of death: Correlations with quality of life of patients with cancer and predictors of Bereaved caregiver's mental health. J Clin Oncol, 28, 4457-64. https://doi.org/10.1200/JCO.2009.26.3863